Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99352, USA.
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15395-400. doi: 10.1073/pnas.1204366109. Epub 2012 Sep 4.
Sensitive detection of low-abundance proteins in complex biological samples has typically been achieved by immunoassays that use antibodies specific to target proteins; however, de novo development of antibodies is associated with high costs, long development lead times, and high failure rates. To address these challenges, we developed an antibody-free strategy that involves PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing) for sensitive selected reaction monitoring (SRM)-based targeted protein quantification. The strategy capitalizes on high-resolution reversed-phase liquid chromatographic separations for analyte enrichment, intelligent selection of target fractions via on-line SRM monitoring of internal standards, and fraction multiplexing before nano-liquid chromatography-SRM quantification. Application of this strategy to human plasma/serum demonstrated accurate and reproducible quantification of proteins at concentrations in the 50-100 pg/mL range, which represents a major advance in the sensitivity of targeted protein quantification without the need for specific-affinity reagents. Application to a set of clinical serum samples illustrated an excellent correlation between the results obtained from the PRISM-SRM assay and those from clinical immunoassay for the prostate-specific antigen level.
在复杂的生物样本中,对低丰度蛋白质的敏感检测通常是通过使用针对靶蛋白的特异性抗体的免疫测定来实现的;然而,从头开发抗体与高成本、长开发周期和高失败率相关。为了解决这些挑战,我们开发了一种无抗体的策略,该策略涉及 PRISM(高压、高分辨率分离与智能选择和多路复用),用于基于敏感选择反应监测(SRM)的靶向蛋白质定量。该策略利用高效液相色谱分离进行分析物富集,通过在线 SRM 监测内标对目标馏分进行智能选择,然后在纳流液相色谱-SRM 定量之前进行馏分多路复用。该策略在人血浆/血清中的应用证明了在 50-100 pg/mL 范围内的蛋白质浓度的准确和可重现的定量,这代表了在无需特异性亲和试剂的情况下靶向蛋白质定量的灵敏度的重大进展。对一组临床血清样本的应用表明,PRISM-SRM 测定获得的结果与前列腺特异性抗原水平的临床免疫测定结果之间具有极好的相关性。